<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001780117</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001817229</issuerCik>
      <issuerName>Vor Biopharma Inc.</issuerName>
      <secFileNumber>001-39979</secFileNumber>
      <issuerAddress>
        <com:street1>500 BOYLSTON STREET</com:street1>
        <com:street2>SUITE 1350</com:street2>
        <com:city>BOSTON</com:city>
        <com:stateOrCountry>MA</com:stateOrCountry>
        <com:zipCode>02116</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>617-655-6580</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>RA Capital Nexus Fund, L.P.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Director</relationshipToIssuer>
        <relationshipToIssuer>10% Stockholder</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>BTIG, LLC</name>
        <address>
          <com:street1>350 Bush Street</com:street1>
          <com:street2>9th Floor</com:street2>
          <com:city>San Francisco</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94104</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>8430</noOfUnitsSold>
      <aggregateMarketValue>254754.60</aggregateMarketValue>
      <noOfUnitsOutstanding>6841134</noOfUnitsOutstanding>
      <approxSaleDate>10/15/2025</approxSaleDate>
      <securitiesExchangeName>NASDAQ GS</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common</securitiesClassTitle>
      <acquiredDate>02/12/2019</acquiredDate>
      <natureOfAcquisitionTransaction>Private Financing</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Vor Biopharma Inc.  </nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>14016</amountOfSecuritiesAcquired>
      <paymentDate>02/05/2020</paymentDate>
      <natureOfPayment>Wire</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <noticeSignature>
      <noticeDate>10/15/2025</noticeDate>
      <signature>David Crowe</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
